Amylyx Pharmaceuticals, Inc. (AMLX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts AMLX Hot Sheet
Join SI Premium – FREE
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q2 EPS of ($0.46), in-line with the analyst estimate of ($0.46).
For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
- Active options: AMD INTC CRWV PLTR IREN BE SOFI MSFT NFLX GOOGL MRNA HOOD
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
